ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME

Clinical trials for ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME explained in plain language.

Never miss a new study

Get alerted when new ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME trials appear

Sign up with your email to follow new studies for ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 2 Terminated 1

Experimental drug shows promise for rare immune disorder, but study cut short

Disease control Terminated

This study tested the long-term safety and effectiveness of a drug called CDZ173 in people with APDS/PASLI, a rare genetic condition that causes a weak immune system and swollen lymph nodes. The 37 participants had already taken CDZ173 or a similar drug in a previous study. The t…

Matched conditions: ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME

Phase: PHASE2, PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control

Last updated Jun 27, 2026 12:01 UTC

ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME

Get alerted when new ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME trials appear

Experimental drug shows promise for rare immune disorder, but study cut short